70 phenotypes from 7 alleles in 8 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Gcgrem1Tshu/Gcgrem1Tshu involves: C57BL/6J	decreased fasting circulating glucose level	J:279017
Gcgrem2Smoc/Gcgrem2Smoc C57BL/6J-Gcgrem2Smoc	abnormal liver physiology	J:300368
	abnormal pancreatic alpha cell morphology	J:300368
	decreased body fat mass	J:300368
	decreased fasting circulating glucose level	J:300368
	improved glucose tolerance	J:300368
	increased circulating glucagon level	J:300368
	increased liver weight	J:300368
	increased pancreas weight	J:300368
	increased pancreatic alpha cell proliferation	J:300368
Gcgrtm1(GCGR)Kasu/Gcgrtm1(GCGR)Kasu involves: 129S7/SvEvBrd * C57BL/6J	no abnormal phenotype detected	J:58436
Gcgrtm1.1(KOMP)Vlcg/Gcgrtm1.1(KOMP)Vlcg C57BL/6N-Gcgrtm1.1(KOMP)Vlcg/Ucd	abnormal bone structure	J:211773
	abnormal kidney morphology	J:211773
	decreased circulating insulin level	J:211773
	decreased fasting circulating glucose level	J:211773
	decreased mean corpuscular hemoglobin concentration	J:211773
	decreased total body fat amount	J:211773
	enlarged kidney	J:211773
	female infertility	J:211773
	improved glucose tolerance	J:211773
	increased blood urea nitrogen level	J:211773
	increased bone mineral content	J:211773
	increased circulating calcium level	J:211773
	increased circulating cholesterol level	J:211773
	increased kidney weight	J:211773
	increased lean body mass	J:211773
	increased mean corpuscular volume	J:211773
	increased startle reflex	J:211773
	male infertility	J:211773
Gcgrtm1Jcp/Gcgrtm1Jcp DBA/1LacJ-Gcgrtm1Jcp	abnormal exocrine gland morphology	J:176507
	abnormal pancreatic acinar cell morphology	J:176507
	abnormal pancreatic alpha cell differentiation	J:176507
	abnormal pancreatic alpha cell morphology	J:176507
	abnormal pancreatic islet morphology	J:176507
	decreased abdominal adipose tissue amount	J:176507
	decreased body weight	J:176507
	decreased circulating glucose level	J:176507
	decreased circulating insulin level	J:176507
	decreased liver weight	J:176507
	decreased subcutaneous adipose tissue amount	J:176507
	decreased susceptibility to age-related hepatic steatosis	J:176507
	decreased susceptibility to weight gain	J:176507
	enlarged pancreas	J:176507
	enlarged pancreatic islets	J:176507
	normal homeostasis/metabolism phenotype	J:73926
	increased circulating glucagon level	J:73926, J:176507
	increased glucagonoma incidence	J:176507
	increased pancreas tumor incidence	J:176507
	increased pancreatic beta cell proliferation	J:176507
	pancreatic islet hyperplasia	J:176507
Gcgrtm1Mjch/Gcgrtm1Mjch involves: 129 * C57BL/6J * SJL	decreased carbon dioxide production	J:216393
	decreased circulating insulin level	J:208604
	decreased food intake	J:216393
	decreased locomotor activity	J:216393
	decreased oxygen consumption	J:216393
	decreased susceptibility to diet-induced non-insulin dependent diabetes	J:216393
	decreased susceptibility to diet-induced obesity	J:216393
	improved glucose tolerance	J:208604
	increased bile salt level	J:208604
	increased circulating glucagon level	J:208604
	increased glucagon secretion	J:208604
	increased insulin sensitivity	J:208604
	increased pancreas weight	J:208604
	increased pancreatic alpha cell mass	J:208604
	increased pancreatic alpha cell number	J:208604
	increased pancreatic alpha cell proliferation	J:208604
	increased pancreatic beta cell mass	J:208604
Gcgrtm1Mjch/Gcgrtm1Mjch involves: 129/Sv * C57BL/6J * SJL	abnormal circulating amino acid level	J:251829
	abnormal pancreatic alpha cell morphology	J:251829
	decreased brown adipose tissue amount	J:81772
	decreased circulating glucose level	J:81772
	decreased circulating insulin level	J:251829
	decreased circulating leptin level	J:81772
	decreased gonadal fat pad weight	J:81772
	decreased interscapular fat pad weight	J:81772
	decreased litter size	J:81772
	decreased total body fat amount	J:81772
	decreased triglyceride level	J:81772
	normal endocrine/exocrine gland phenotype	J:251829
	hypoglycemia	J:81772, J:251829
	improved glucose tolerance	J:81772
	increased body mass index	J:81772
	increased circulating glucagon level	J:81772, J:251829
	increased circulating LDL cholesterol level	J:81772
	increased pancreatic alpha cell number	J:251829
	pancreatic islet hyperplasia	J:81772, J:251829
	postnatal lethality, incomplete penetrance	J:81772
	prenatal lethality, incomplete penetrance	J:81772
Gcgrtm2.1Mjch/Gcgrtm2.1Mjch Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+ involves: C57BL/6 * DBA * SJL	abnormal glucose homeostasis	J:208604
	decreased circulating glucose level	J:208604
	decreased circulating insulin level	J:208604
	hypoglycemia	J:208604
	improved glucose tolerance	J:208604
	increased bile salt level	J:208604
	increased circulating glucagon level	J:208604
	increased insulin sensitivity	J:208604
	increased pancreas weight	J:208604
	increased pancreatic alpha cell number	J:208604
	increased pancreatic alpha cell proliferation	J:208604
	increased pancreatic beta cell mass	J:208604